Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972164 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3971604 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3980411 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3961635 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3972629 | 0.99 | MEN1 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3972647 | 0.97 | MEN1 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3960521 | 0.90 | MEN1 (0.45) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL3950407 | 0.88 | STS (0.45) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL3980468 | 0.88 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3976438 | 0.88 | SLC6A2 (0.47) | SLC6A2MEN1KMT2ACYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531543-B2 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1673358-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037808-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | HTR5A, PNMT, HTR3A | SLC6A2 49/4885SLC6A3 100/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.